New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells

Clinical Cancer Research

Volumn 16, Issue 10, 2010, Pages 2792-2802

  Nakashima, Takayuki ^a   Ishii, Toshihiko ^a   Tagaya, Hisashi ^a   Seike, Toshihiro ^a   Nakagawa, Hiroshi ^a   Kanda, Yutaka ^a   Akinaga, Shiro ^a   Soga, Shiro ^a   Shiotsu, Yukimasa ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 ETHYL 3,5 DIHYDROXY 6 [3 METHOXY 4 (2 MORPHOLIN 4 YLETHOXY)BENZOYL]PHENYL] N,N BIS(2 METHOXYETHYL)ACETAMIDE; BETA ACTIN; CHAPERONE; CYCLIN D1; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLOPHOSPHAMIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GREEN FLUORESCENT PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOGLOBULIN HEAVY CHAIN; INITIATION FACTOR 4E BINDING PROTEIN 1; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR BETA; KW 2478; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RAF PROTEIN; SOMATOMEDIN C RECEPTOR; TANESPIMYCIN; TRANSCRIPTION FACTOR C MAF; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CANCER INHIBITION; CANCER MODEL; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; DRUG PROTEIN BINDING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, NUDE; MORPHOLINES; MULTIPLE MYELOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952383375     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3112     Document Type: Article

References (41)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351: 1860-1873
2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-598 (Pubitemid 47106630)
3. Agnelli L, Bicciato S, Mattioli M, et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 2005;23:7296-7306 (Pubitemid 46202343)
4. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-772
5. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007;32:517-530 (Pubitemid 46708702)
6. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994;91:8324-8328 (Pubitemid 24273656)
7. Soga S, Kozawa T, Narumi H, et al. Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway. J Biol Chem 1998;273:822-828 (Pubitemid 28049172)
8. Soga S, Neckers LM, Schulte TW, et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res 1999; 59:2931-2938 (Pubitemid 29283134)
9. Shiotsu Y, Neckers LM, Wortman I, et al. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 2000;96:2284-2291
10. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003-4009 (Pubitemid 32720963)
11. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-993 (Pubitemid 34517631)
12. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-2144
13. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003;3:377-383
14. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008;13:38-43.
15. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092-1100 (Pubitemid 43156310)
16. Chatterjee M, Jain S, Stühmer T, et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007;109:720-728 (Pubitemid 46105974)
17. Mitsiades C, Richardson P, Chanan-Khan A, et al. Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM). ASCO (American Society of Clinical Oncology) Annual Meeting 2005;Abstract No. 3056.
18. Richardson PG, Chanan-Khan AA, Alsina M, et al. Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): Interim results of a phase 1 trial. Blood (ASH Annual Meeting Abstracts) 2005;106:Abstract No. 361.
19. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998;58:2385-2396
20. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-1949
21. Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-2860 (Pubitemid 351556284)
22. Karapanagiotou EM, Syrigos K, Saif MW. Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs 2009;18:161-174
23. Agatsuma T, Ogawa H, Akasaka K, et al. Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg Med Chem 2002;10:3445-3454
24. Nakashima T, Tanaka R, Yamashita Y, Kanda Y, Hara M. Aranorosin and a novel derivative inhibit the anti-apoptotic functions regulated by Bcl-2. Biochem Biophys Res Commun 2008;377:1085-1090
25. Gazdar AF, Oie HK, Kirsch IR, Hollis GF. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 1986;67:1542-1549
26. Katagiri S, Yonezawa T, Kuyama J, et al. Two distinct human myeloma cell lines originating from one patient with myeloma. Int J Cancer 1985;36:241-246 (Pubitemid 15243451)
27. Lang SA, Moser C, Gaumann A, et al. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1α autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 2007;13:6459-6468 (Pubitemid 350075036)
28. Ronchetti D, Greco A, Compasso S, et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001;20:3553-3562
29. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 2000;97:228-233 (Pubitemid 30055813)
30. Lombardi L, Poretti G, Mattioli M, et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 2007; 46:226-238 (Pubitemid 46155318)
31. O'Keeffe B, Fong Y, Chen D, Zhou S, Zhou Q. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J Biol Chem 2000;275:279-287 (Pubitemid 30038983)
32. Armengol G, Rojo F, Castellví J, et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007;67:7551-7555
33. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006;31:164-172 (Pubitemid 43361923)
34. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-837
35. Stühmer T, Zöllinger A, Siegmund D, et al. Signalling profile and anti-tumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 2008;22:1604-1612
36. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-1783 (Pubitemid 46628473)
37. Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 2008;29:302-313
38. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005;106:2513-2519 (Pubitemid 41510827)
39. MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005;65:5399-5407
40. Mitsiades CS, Mitsiades NS, Bronson RT, et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 2003;63:6689-6696
41. Xin X, Abrams TJ, Hollenbach PW, et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 2008; 14:2075-2081